A Clinical Trial of PRAX-944 in Participants With Essential Tremor
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This is a 2-part clinical trial to evaluate the efficacy, safety, and tolerability of 40 and
120 mg oral PRAX-944 compared to placebo in the treatment of adults with essential tremor.
Part A is designed to study the dose titration from 20 to 40 mg every morning (QAM) (ie, 2
weeks with 7 days at each dose level). Part B is designed to study the dose titration from 20
to up to 120 mg QAM with at least 14 days of dosing at the highest tolerated dose for each
participant. Blood levels of PRAX-944 will also be measured throughout the trial and
pharmacokinetics will be evaluated.